Swoboda W, Turnheim E, Frisch H, Spona J
Padiatr Padol Suppl. 1977(5):109-20.
A synthetic steroid compound derived from testosteron (isoxazol-ethisterone), Danazol, with gonadotropin-depressing activity, was used in the treatment of 4 cases of idiopathis sexual precocity (age 2 1/2 to 4 years) and in 10 cases of severe pubertal gynaecomastia. In sexual precocity the suppression of menstruation as well as of breast-enlargement was good, while the suppression of acceleration of longitudinal growth and bone maturation was inferior compared with cyproteron-acetate. In most boys with gynaecomastia a marked regression of breast enlargement occurred within a few weeks or months. With the dosage used (200-300 mg/day in the sexual precocity patients, 300-400 mg in the gynaecomastia patients) the changes in plasma hormone levels (LH, FSH, progesterone, estradiol, testosterone) were within a non significant range. Depression of testosterone seemed to be a rather regular finding. No untoward side-effects of the medication were noticed in the 14 patients studied. In summary, Danazol did not show any advantages compared with the compounds used in the treatment of isosexual precocity sofar. In contrast, the drug proved to have useful effects in pubertal gynecomastia, a condition which in severe degrees certainly deserves medical treatment.
一种从睾酮（异恶唑 - 乙炔睾酮）衍生而来的具有促性腺激素抑制活性的合成类固醇化合物——达那唑，被用于治疗4例特发性性早熟（年龄2.5至4岁）患儿以及10例重度青春期男性乳房发育症患者。在性早熟病例中，月经及乳房增大的抑制效果良好，然而与醋酸环丙孕酮相比，纵向生长加速及骨骼成熟的抑制效果较差。在大多数患有男性乳房发育症的男孩中，乳房增大在数周或数月内显著消退。就所使用的剂量而言（性早熟患者为200 - 300毫克/天，男性乳房发育症患者为300 - 400毫克），血浆激素水平（促黄体生成素、促卵泡生成素、孕酮、雌二醇、睾酮）的变化处于无显著意义的范围内。睾酮水平降低似乎是一个较为常见的现象。在所研究的14例患者中未观察到该药物的任何不良副作用。总之，到目前为止，与用于治疗同性性早熟的其他化合物相比，达那唑未显示出任何优势。相比之下，该药物在青春期男性乳房发育症中被证明具有有益效果，这种病症在严重程度上确实值得医学治疗。
